[Translation] A clinical study to evaluate the safety, tolerability, pharmacokinetics, preliminary efficacy, and correlation between efficacy and AKR1C3 expression of AST-001 in the treatment of patients with malignant tumors
主要目的:
- 评估实体瘤受试者接受AST-001静脉输注给药的安全性和耐受性
- 评估实体瘤受试者中AST-001及其主要代谢产物AST 2660的药代动力学特征
- 确定实体瘤受试者接受AST-001单药治疗的最大耐受剂量(MTD),并确定II期临床推荐剂量(RP2D)
次要目的:
- 根据受试者的客观缓解率(ORR)、疾病控制率(DCR)、缓解持续时间(DOR)和无进展生存期(PFS)初步评估AST-001单药治疗恶性肿瘤的疗效
- 探索肿瘤组织经免疫组织化学(IHC)确定的AKR1C3表达与疗效之间的关系
- 评估AST-001在人体内的代谢产物谱
探索性目的:
- 探索DNA损伤修复相关基因的突变情况
[Translation] Primary objectives:
- To evaluate the safety and tolerability of AST-001 intravenous infusion in subjects with solid tumors
- To evaluate the pharmacokinetic characteristics of AST-001 and its main metabolite AST 2660 in subjects with solid tumors
- To determine the maximum tolerated dose (MTD) of AST-001 monotherapy in subjects with solid tumors and determine the recommended dose (RP2D) for Phase II clinical trials
Secondary objectives:
- To preliminarily evaluate the efficacy of AST-001 monotherapy in the treatment of malignant tumors based on the objective response rate (ORR), disease control rate (DCR), duration of response (DOR) and progression-free survival (PFS) of the subjects
- To explore the relationship between AKR1C3 expression determined by immunohistochemistry (IHC) in tumor tissues and efficacy
- To evaluate the metabolite spectrum of AST-001 in humans
Exploratory objectives:
- To explore the mutation status of genes related to DNA damage repair